P-34 ALBUMIN-BILIRUBIN GRADE ANALYSIS OF OVERALL SURVIVAL WITH ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA

P-34 ALBUMIN-BILIRUBIN GRADE ANALYSIS OF OVERALL SURVIVAL WITH ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA

Conflict of interest: No Introduction and Objectives: Atezolizumab-bevacizumab (atezo-bev) is currently recommended as first-line therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness in patients with albumin-bilirrubin (ALBI) grade 2 has been questioned...

Full description

Saved in:
Bibliographic Details
Main Authors: Cristina Cheinquer Coelho Borges, Alexandre de Araújo, Mario Alvares-da-Silva Reis, Rui Weschenfelder, Hugo Cheinquer
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Annals of Hepatology
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268124004319
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items